Infections in pediatric acute myeloid leukemia: Lessons learned and unresolved questions

Pediatric Blood and Cancer

Volumn 51, Issue 4, 2008, Pages 458-460

  Sung, Lillian ^a   Aplenc, Richard ^b,f   Zaoutis, Theo ^b   Groll, Andreas H ^c   Gibson, Brenda ^c   Lehrnbecher, Thomas ^d,e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; PENICILLIN DERIVATIVE; POSACONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC PROPHYLAXIS; ASPERGILLOSIS; ASPERGILLUS; BACTEREMIA; CANDIDA; CHILD; CHILD HOSPITALIZATION; CHILDHOOD LEUKEMIA; DISEASE SEVERITY; ESCHERICHIA COLI; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION; MORBIDITY; MORTALITY; MUCORMYCOSIS; NONHUMAN; NOTE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS INFECTION;

BACTERIAL INFECTIONS; CHILD; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYCOSES;

EID: 50249087886     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21613     Document Type: Note

References (23)

1. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: Analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004;18:72-77.
2. Sung L, Lange BJ, Gerbing RB, et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007;110:3532.
3. Pizzo PA, Rubin M, Freifeld A, et al. The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr 1991;119:679-694.
4. Gassas A, Grant R, Richardson S, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol 2004;22:1222-1227.
5. Brunet AS, Ploton C, Galambrun C, et al. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. Pediatr Blood Cancer 2006;47:765-772.
6. Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006;117:e711-e716.
7. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
8. Bochennek K, Abolmaali N, Wittekindt B, et al. Diagnostic approaches for immunocompromised paediatric patients with pulmonary infiltrates. Clin Microbiol Infect 2006;12:199-201.
9. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14.
10. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: A mulitcenter retrospective analysis of 139 contemporary cases. Pediatrics 2008;121:e1286.
11. International Pediatric Fungal Network. http://pediatrics.duke.edu/ modules/div_peds_pfn.
12. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004;22:4384-4393.
13. Stevens RF, Hann IM, Wheatley K, et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998;101:130-140.
14. Lehrnbecher T, Bernig T, Hanisch M, et al. Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005;19:1745-1750.
15. Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-995.
16. van de Wetering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: A systematic review of randomised controlled trials. Eur J Cancer 2005;41:1372-1382.
17. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977-987.
18. Bruckner L, Gigliotti F. Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance. Semin Pediatr Infect Dis 2006;17:153-160.
19. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359.
20. Humphreys H. Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence? J Hosp Infect 2004;56:93-100; quiz 163.
21. Lee OK, Johnston L. A systematic review for effective management of central venous catheters and catheter sites in acute care paediatric patients. Worldviews Evid Based Nurs 2005;2:4-13; discussion 14-15.
22. Simon A, Bode U, Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: An update. Clin Microbiol Infect 2006;12:606-620.
23. Raad I, Hanna H, Maki D. Intravascular catheter-related infections: Advances in diagnosis, prevention, and management. Lancet Infect Dis 2007;7:645-657.